Japan’s Sumitomo merges oncology arms Tolero Pharma, Boston Biomedical

Medical drugs in a pharmacy. Credit: Flickr/epSos .de

Sumitomo Dainippon Pharma (SDP) has merged two of its US-based wholly owned subsidiaries, Tolero Pharmaceuticals and Boston Biomedical, to form Sumitomo Dainippon Pharma Oncology, the company said in a statement Wednesday.

Hiroshi Nomura, CEO of SDP, said merging the two units would help the company make oncology its core business.

“Over the last decade, these formerly separate organizations have expanded our oncology pipeline to include multiple advanced assets and early discovery programs,” Nomura said in a statement.

SDP has tapped Patricia Andrews, currently CEO of Boston Biomedical, as the CEO and global head of oncology.

SDP Oncology will also house the Japanese firm’s oncology research teams in Japan, DSP Cancer Institute and Oncology Clinical Development Unit, the statement said.

The new entity’s discovery, research and development programs will include oncogenic pathways, survival mechanisms and novel protein interactions.

It added that its portfolio has both preclinical and advanced-stage assets for multiple solid tumours and hematologic malignancies, including metastatic colorectal cancer, glioblastoma, myelofibrosis and myelodysplastic syndrome.

Last year, SDP paid $3 billion for a 10 per cent stake in Switzerland-based Roivant Sciences, taking over units developing treatments for prostate cancer and other diseases.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.